查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813962

美國活性藥物成分市場規模、佔有率和趨勢分析報告：按合成類型、製造商、類型、應用和細分市場預測，2025-2033 年

U.S. Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report By Type Of Synthesis (Biotech, Synthetic), By Type Of Manufacturer (Captive, Mesrchant), By Type, By Application, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國活性藥物成分市場摘要

預計 2024 年美國活性藥物成分市場價值將達到 874.6 億美元，到 2033 年將達到 1,319.8 億美元，2025 年至 2033 年的複合年成長率為 4.6%。

癌症、心血管疾病、糖尿病和呼吸系統疾病等慢性疾病的發生率不斷上升，推動著市場成長。受這些疾病影響的患者群體不斷擴大，推動了對先進療法的持續需求，包括小分子和生物製藥的活性藥物成分(原料藥)。隨著人口老化，需要長期治療的老年人比例穩步上升，這使得 API 成為醫療保健管理的關鍵組成部分。例如，2025 年 8 月，唐納德·川普總統簽署了一項行政命令，建立戰略原料藥儲備 (SAPIR)，以儲存對國家健康和安全至關重要的藥物成分。這項由美國衛生與公共服務部支持的計劃突顯了 COVID-19 大流行暴露的供應鏈漏洞。

推動美國活性藥物成分市場發展的另一個關鍵因素是生技藥品和生物相似藥的快速擴張，它們正在重塑各個治療領域的治療方法。單株抗體、重組蛋白和疫苗等生物製劑需要高度複雜、高價值的生技藥品原料藥比傳統的小分子原料藥更難製造。不斷上漲的醫療成本加速了人們採用生物相似藥作為具有成本效益的替代品，為原料藥製造商提供了新的成長途徑。隨著腫瘤學、免疫學和罕見疾病需求的不斷成長，製造商正在採用生物製程最佳化和細胞培養創新等先進技術。例如，2024 年 1 月，FDA 發布了指南草案，將人用藥物的 CGMP 要求（ICH Q7）擴展到原料藥，加強了監管並統一了標準。這項轉變強調創新，並使美國公司成為全球生技藥品供應鏈的領導者。

美國活性藥物成分市場在很大程度上受到嚴格的法律規範的影響，這些監督旨在確保產品品質、安全性和一致性。遵守FDA標準對於維護信任和推動生產實踐的持續改進至關重要。例如，2024年6月，美國食品藥物管理局（FDA）修訂了21 CFR第211部分，以加強原料藥（包括活性藥物成分）的品質保證，並增強現行良好生產規範（CGMP），確保原料藥符合最高的安全性和有效性標準。這些監管更新鼓勵製造商採用先進的系統，從而增強了美國活性藥物成分行業的可信度和公信力。

這些監管改進措施預計將透過提高生產透明度和一致性來支持美國原料藥市場的長期成長。更新後的CGMP框架鼓勵製造商實施更強大的品管機制、先進的監控技術和標準化的操作程序。這不僅降低了污染和產品召回的風險，也提高了大規模生產的效率。透過使行業實踐與更高的品質基準保持一致，FDA正在創造一個企業能夠透過創新競爭同時確保患者安全的環境。因此，製藥公司可以放心地擴展產品系列。整體而言，這些措施增強了美國原料藥在國內和全球供應鏈中的可靠性。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國活性藥物成分市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章美國活性藥物成分市場：合成型業務分析

  • 2024年及2033年合成橡膠市場佔有率
  • 綜合細分儀表板的類型
  • 2021 年至 2033 年按合成類型分類的市場規模、預測與趨勢分析
  • 生物技術
  • 合成

第5章美國活性藥物成分市場：按製造商類型進行的業務分析

  • 2024 年及 2033 年各製造商市場佔有率
  • 製造商類型細分儀表板
  • 市場規模、預測和趨勢分析（按製造商類型，2021-2033 年）
  • 專屬式API
  • 商家 API
  • 商家 API 市集（按類型）
  • 商家 API 市場（依合成類型）

第6章美國活性藥物成分市場：按類型分類的業務分析

  • 2024 年及 2033 年各類型市場佔有率
  • 類型細分儀表板
  • 市場規模、預測與趨勢分析（按類型，2021-2033 年）
  • 通用 API
  • 創新 API

第7章美國活性藥物成分市場：應用業務分析

  • 2024 年和 2033 年應用市場佔有率
  • 應用程式細分儀表板
  • 市場規模、預測與趨勢分析（按應用，2021-2033 年）
  • 心臟病學
  • 腫瘤學
  • 中樞神經系統和神經病學
  • 整形外科
  • 內分泌學
  • 呼吸系統醫療設備
  • 胃腸病學
  • 腎臟病學
  • 眼科
  • 其他

第8章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • AbbVie Inc.
    • Viatris Inc.
    • Fresenius Kabi AG
    • Curia
    • Pfizer Inc.（Pfizer Center One）
    • Bristol-Myers Squibb Company
    • Catalent, Inc.
    • Ampac Fine Chemicals（AFC）
    • Amgen Inc.
    • Johnson &Johnson
Product Code: GVR-4-68040-309-1

U.S. Active Pharmaceutical Ingredients Market Summary

The U.S. active pharmaceutical ingredients market size was estimated at USD 87.46 billion in 2024, is projected to reach USD 131.98 billion by 2033, growing at a CAGR of 4.6% from 2025 to 2033. The rising prevalence of chronic diseases such as cancer, cardiovascular disorders, diabetes, and respiratory illnesses drives the market growth. The expanding patient pool suffering from these conditions are fueling sustained demand for advanced therapies, including both small-molecule and biologic APIs. With an aging demographic, the proportion of elderly individuals requiring long-term treatment is steadily increasing, positioning APIs as a cornerstone of healthcare management. For instance, in August 2025, President Donald Trump signed an executive order establishing the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to stockpile critical drug components for national health and security. Supported by the U.S. Department of Health and Human Services, this initiative highlighted supply chain vulnerabilities exposed by the COVID-19 pandemic.

Another key factor driving the U.S. active pharmaceutical ingredients market is the rapid expansion of biologics and biosimilars, which are reshaping treatment approaches across therapeutic areas. Biologics such as monoclonal antibodies, recombinant proteins, and vaccines require highly complex, high-value APIs that are more difficult to manufacture than conventional small-molecule APIs. Rising healthcare costs have accelerated the adoption of biosimilars as cost-effective alternatives, creating new growth avenues for API producers. As demand increases across oncology, immunology, and rare diseases, manufacturers are adopting advanced techniques such as bioprocess optimization and cell culture innovation. For instance, in January 2024, the FDA issued draft guidance extending human drug CGMP requirements (ICH Q7) to veterinary APIs, strengthening oversight and aligning standards. This shift underscores innovation and positions U.S.-based firms as global biologics supply chain leaders.

The U.S. active pharmaceutical ingredients market is heavily shaped by stringent regulatory oversight that ensures product quality, safety, and consistency. Compliance with FDA standards plays a critical role in maintaining trust and driving continuous improvements in manufacturing practices. For instance, in June 2024, the U.S. Food and Drug Administration (FDA) amended 21 CFR Part 211, enhancing Current Good Manufacturing Practices (CGMP) for drug products, including APIs, to strengthen quality assurance and ensure APIs meet the highest standards of safety and efficacy. Such regulatory updates push manufacturers to adopt advanced systems, reinforcing the credibility and reliability of the U.S. API industry.

These regulatory enhancements are expected to support long-term growth in the U.S. API market by fostering greater transparency and consistency in production. The updated CGMP framework encourages manufacturers to implement more robust quality-control mechanisms, advanced monitoring technologies, and standardized operating procedures. This not only reduces the risk of contamination and product recalls but also improves efficiency in large-scale manufacturing. By aligning industry practices with higher quality benchmarks, the FDA creates an environment where companies can compete through innovation while ensuring patient safety. In turn, pharmaceutical firms are better positioned to confidently expand their product portfolios. Overall, these measures strengthen the reliability of U.S.-produced APIs in both domestic and global supply chains.

U.S. Active Pharmaceutical Ingredients Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. active pharmaceutical ingredients market report based on type of synthesis, type of manufacturer, type, and application.

  • Type of Synthesis Outlook (Revenue, USD Billion, 2021 - 2033)
  • Biotech
    • Biotech APIs Market, By Type
    • Generic API
    • Innovative API
    • Biotech APIs Market, By Product
    • Monoclonal Antibodies
    • Hormones
    • Cytokines
    • Recombinant Proteins
    • Therapeutic Enzymes
    • Vaccines
    • Blood Factors
  • Synthetic
    • Synthetic APIs Market, By Type
    • Generic API
    • Innovative API
  • Type of Manufacturer Outlook (Revenue, USD Billion, 2021 - 2033)
  • Captive APIs
  • Merchant APIs
    • Merchant APIs Market, By Type
    • Generic API
    • Innovative API
    • Merchant APIs Market, By Type of Synthesis
    • Biotech
    • Synthetic
  • Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Generic API
  • Innovative API
  • Application Outlook (Revenue, USD Billion, 2021 - 2033)
  • Cardiology
  • Oncology
  • CNS and Neurology
  • Orthopedic
  • Endocrinology
  • Pulmonology
  • Gastroenterology
  • Nephrology
  • Ophthalmology
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type of Synthesis
    • 1.2.2. Type of Manufacturer
    • 1.2.3. Type
    • 1.2.4. Application
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Source
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Source
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Active Pharmaceutical Ingredients Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Active Pharmaceutical Ingredients Market: Type of Synthesis Business Analysis

  • 4.1. Type of Synthesis Market Share, 2024 & 2033
  • 4.2. Type of Synthesis Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type of Synthesis, 2021 to 2033 (USD Billion)
  • 4.4. Biotech
    • 4.4.1. Biotech Market, 2021 - 2033 (USD Billion)
    • 4.4.2. Biotech APIs Market, By Type
      • 4.4.2.1. Biotech APIs Market, By Type Market, 2021 - 2033 (USD Billion)
      • 4.4.2.2. Generic API
        • 4.4.2.2.1. Generic API Market, 2021 - 2033 (USD Billion)
      • 4.4.2.3. Innovative API
        • 4.4.2.3.1. Innovative API Market, 2021 - 2033 (USD Billion)
    • 4.4.3. Biotech APIs Market, By Product
      • 4.4.3.1. Biotech APIs Market, By Product Market, 2021 - 2033 (USD Billion)
      • 4.4.3.2. Monoclonal Antibodies
        • 4.4.3.2.1. Monoclonal Antibodies Market, 2021 - 2033 (USD Billion)
      • 4.4.3.3. Hormones
        • 4.4.3.3.1. Hormones Market, 2021 - 2033 (USD Billion)
      • 4.4.3.4. Cytokines
        • 4.4.3.4.1. Cytokines Market, 2021 - 2033 (USD Billion)
      • 4.4.3.5. Recombinant Proteins
        • 4.4.3.5.1. Recombinant Proteins Market, 2021 - 2033 (USD Billion)
      • 4.4.3.6. Therapeutic Enzymes
        • 4.4.3.6.1. Therapeutic Enzymes Market, 2021 - 2033 (USD Billion)
      • 4.4.3.7. Vaccines
        • 4.4.3.7.1. Vaccines Market, 2021 - 2033 (USD Billion)
      • 4.4.3.8. Blood Factors
        • 4.4.3.8.1. Blood Factors Market, 2021 - 2033 (USD Billion)
  • 4.5. Synthetic
    • 4.5.1. Synthetic Market, 2021 - 2033 (USD Billion)
    • 4.5.2. Synthetic APIs Market, By Type
      • 4.5.2.1. Synthetic APIs Market, By Type Market, 2021 - 2033 (USD Billion)
      • 4.5.2.2. Generic API
        • 4.5.2.2.1. Generic API Market, 2021 - 2033 (USD Billion)
      • 4.5.2.3. Innovative API
        • 4.5.2.3.1. Innovative API Market, 2021 - 2033 (USD Billion)

Chapter 5. U.S. Active Pharmaceutical Ingredients Market: Type of Manufacturer Business Analysis

  • 5.1. Type of Manufacturer Market Share, 2024 & 2033
  • 5.2. Type of Manufacturer Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type of Manufacturer, 2021 to 2033 (USD Billion)
  • 5.4. Captive APIs
    • 5.4.1. Captive APIs Market, 2021 - 2033 (USD Billion)
  • 5.5. Merchant APIs
    • 5.5.1. Merchant APIs Market, 2021 - 2033 (USD Billion)
  • 5.6. Merchant APIs Market, By Type
    • 5.6.1. Merchant APIs Market, By Type Market, 2021 - 2033 (USD Billion)
    • 5.6.2. Generic API
      • 5.6.2.1. Generic API Market, 2021 - 2033 (USD Billion)
    • 5.6.3. Innovative API
      • 5.6.3.1. Innovative API Market, 2021 - 2033 (USD Billion)
  • 5.7. Merchant APIs Market, By Type of Synthesis
    • 5.7.1. Merchant APIs Market, By Type of Synthesis Market, 2021 - 2033 (USD Billion)
    • 5.7.2. Biotech
      • 5.7.2.1. Biotech Market, 2021 - 2033 (USD Billion)
    • 5.7.3. Synthetic
      • 5.7.3.1. Synthetic Market, 2021 - 2033 (USD Billion)

Chapter 6. U.S. Active Pharmaceutical Ingredients Market: Type Business Analysis

  • 6.1. Type Market Share, 2024 & 2033
  • 6.2. Type Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Billion)
  • 6.4. Generic API
    • 6.4.1. Generic API Market, 2021 - 2033 (USD Billion)
  • 6.5. Innovative API
    • 6.5.1. Innovative API Market, 2021 - 2033 (USD Billion)

Chapter 7. U.S. Active Pharmaceutical Ingredients Market: Application Business Analysis

  • 7.1. Application Market Share, 2024 & 2033
  • 7.2. Application Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Billion)
  • 7.4. Cardiology
    • 7.4.1. Cardiology Market, 2021 - 2033 (USD Billion)
  • 7.5. Oncology
    • 7.5.1. Oncology Market, 2021 - 2033 (USD Billion)
  • 7.6. CNS and Neurology
    • 7.6.1. CNS and Neurology Market, 2021 - 2033 (USD Billion)
  • 7.7. Orthopedic
    • 7.7.1. Orthopedic Market, 2021 - 2033 (USD Billion)
  • 7.8. Endocrinology
    • 7.8.1. Endocrinology Market, 2021 - 2033 (USD Billion)
  • 7.9. Pulmonology
    • 7.9.1. Pulmonology Market, 2021 - 2033 (USD Billion)
  • 7.10. Gastroenterology
    • 7.10.1. Gastroenterology Market, 2021 - 2033 (USD Billion)
  • 7.11. Nephrology
    • 7.11.1. Nephrology Market, 2021 - 2033 (USD Billion)
  • 7.12. Ophthalmology
    • 7.12.1. Ophthalmology Market, 2021 - 2033 (USD Billion)
  • 7.13. Others
    • 7.13.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. AbbVie Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Viatris Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Fresenius Kabi AG
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Curia
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Pfizer Inc. (Pfizer Center One)
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Bristol-Myers Squibb Company
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Catalent, Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Ampac Fine Chemicals (AFC)
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Amgen Inc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Johnson & Johnson
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. U.S. active pharmaceutical ingredients market, by Type of Synthesis, 2021 - 2033 (USD Billion)
  • Table 4. U.S. active pharmaceutical ingredients market, by Type of Manufacturer, 2021 - 2033 (USD Billion)
  • Table 5. U.S. active pharmaceutical ingredients market, by Type, 2021 - 2033 (USD Billion)
  • Table 6. U.S. active pharmaceutical ingredients market, by Application, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 U.S. active pharmaceutical ingredients market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 U.S. active pharmaceutical ingredients market dynamics
  • Fig. 11 U.S. active pharmaceutical ingredients market: Porter's five forces analysis
  • Fig. 12 U.S. active pharmaceutical ingredients market: PESTLE analysis
  • Fig. 13 Type of Synthesis market, 2021 - 2033 (USD Billion)
  • Fig. 14 Biotech market, 2021 - 2033 (USD Billion)
  • Fig. 15 Biotech APIs Market, By Type market, 2021 - 2033 (USD Billion)
  • Fig. 16 Generic API market, 2021 - 2033 (USD Billion)
  • Fig. 17 Innovative API market, 2021 - 2033 (USD Billion)
  • Fig. 18 Biotech APIs Market, By Product market, 2021 - 2033 (USD Billion)
  • Fig. 19 Monoclonal Antibodies market, 2021 - 2033 (USD Billion)
  • Fig. 20 Hormones market, 2021 - 2033 (USD Billion)
  • Fig. 21 Cytokines market, 2021 - 2033 (USD Billion)
  • Fig. 22 Recombinant Proteins market, 2021 - 2033 (USD Billion)
  • Fig. 23 Therapeutic Enzymes market, 2021 - 2033 (USD Billion)
  • Fig. 24 Vaccines market, 2021 - 2033 (USD Billion)
  • Fig. 25 Blood Factors market, 2021 - 2033 (USD Billion)
  • Fig. 26 Synthetic market, 2021 - 2033 (USD Billion)
  • Fig. 27 Synthetic APIs Market, By Type market, 2021 - 2033 (USD Billion)
  • Fig. 28 Generic API market, 2021 - 2033 (USD Billion)
  • Fig. 29 Innovative API market, 2021 - 2033 (USD Billion)
  • Fig. 30 Type of Manufacturer market, 2021 - 2033 (USD Billion)
  • Fig. 31 Captive APIs market, 2021 - 2033 (USD Billion)
  • Fig. 32 Merchant APIs market, 2021 - 2033 (USD Billion)
  • Fig. 33 Merchant APIs Market, By Type market, 2021 - 2033 (USD Billion)
  • Fig. 34 Generic API market, 2021 - 2033 (USD Billion)
  • Fig. 35 Innovative API market, 2021 - 2033 (USD Billion)
  • Fig. 36 Merchant APIs Market, By Type of Synthesis market, 2021 - 2033 (USD Billion)
  • Fig. 37 Biotech market, 2021 - 2033 (USD Billion)
  • Fig. 38 Synthetic market, 2021 - 2033 (USD Billion)
  • Fig. 39 Type market, 2021 - 2033 (USD Billion)
  • Fig. 40 Generic API market, 2021 - 2033 (USD Billion)
  • Fig. 41 Innovative API market, 2021 - 2033 (USD Billion)
  • Fig. 42 Application market, 2021 - 2033 (USD Billion)
  • Fig. 43 Cardiology market, 2021 - 2033 (USD Billion)
  • Fig. 44 Oncology market, 2021 - 2033 (USD Billion)
  • Fig. 45 CNS and Neurology market, 2021 - 2033 (USD Billion)
  • Fig. 46 Orthopedic market, 2021 - 2033 (USD Billion)
  • Fig. 47 Endocrinology market, 2021 - 2033 (USD Billion)
  • Fig. 48 Pulmonology market, 2021 - 2033 (USD Billion)
  • Fig. 49 Gastroenterology market, 2021 - 2033 (USD Billion)
  • Fig. 50 Nephrology market, 2021 - 2033 (USD Billion)
  • Fig. 51 Ophthalmology market, 2021 - 2033 (USD Billion)
  • Fig. 52 Others market, 2021 - 2033 (USD Billion)